samedan logo
 
 
spacer
home > white papers > The Role of the CRO in Effective Risk-Based Monitoring - Medpace
WHITE PAPERS
logo_Medpace.JPG

Medpace

phone +1.513.579.9911
email info@medpace.com
web http://www.medpace.com
email Medpace 5375 Medpace Way, Cincinnati, Ohio, 45227

The Role of the CRO in Effective Risk-Based Monitoring

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.

Realizing the potential of RBM requires early planning, analytical expertise, sophisticated tools and process adaptability. Deep cross-functional expertise early in the trial process enhances the ability to assess overall risk, define critical data and processes, develop an integrated plan for addressing risk, and execute a monitoring plan that meets the trialís unique requirements.
The Role of the CRO in Effective Risk-Based Monitoring
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>


White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>


Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement